Compare Stocks: CDIO, ENLV, MRKR, and LGVN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CDIO Cardio Diagnostics	$1.83 -0.5%	$1.84	$0.97 ▼ $7.91	$5.45M	2.28	50,592 shs	89,781 shs
ENLV Enlivex Therapeutics	$1.16 -7.2%	$3.78	$1.13 ▼ $27.15	$21.86M	1.42	287,570 shs	293,981 shs
LGVN Longeveron	$6.58 -2.9%	$6.92	$4.75 ▼ $12.30	$21.62M	-0.25	75,566 shs	43,874 shs
MRKR Marker Therapeutics	$1.24 -0.8%	$1.31	$0.83 ▼ $2.46	$20.84M	1.53	80,028 shs	42,935 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CDIO Cardio Diagnostics	-0.54%	-2.14%	+5.17%	-6.63%	-52.96%
ENLV Enlivex Therapeutics	-7.20%	-21.36%	-45.02%	-89.11%	-92.70%
LGVN Longeveron	-2.95%	-3.24%	-11.33%	-9.86%	-19.35%
MRKR Marker Therapeutics	-0.80%	-15.07%	+0.81%	-12.68%	+43.10%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CDIO Cardio Diagnostics	$1.83 -0.5%	$1.84	$0.97 ▼ $7.91	$5.45M	2.28	50,592 shs	89,781 shs
ENLV Enlivex Therapeutics	$1.16 -7.2%	$3.78	$1.13 ▼ $27.15	$21.86M	1.42	287,570 shs	293,981 shs
LGVN Longeveron	$6.58 -2.9%	$6.92	$4.75 ▼ $12.30	$21.62M	-0.25	75,566 shs	43,874 shs
MRKR Marker Therapeutics	$1.24 -0.8%	$1.31	$0.83 ▼ $2.46	$20.84M	1.53	80,028 shs	42,935 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CDIO Cardio Diagnostics	-0.54%	-2.14%	+5.17%	-6.63%	-52.96%
ENLV Enlivex Therapeutics	-7.20%	-21.36%	-45.02%	-89.11%	-92.70%
LGVN Longeveron	-2.95%	-3.24%	-11.33%	-9.86%	-19.35%
MRKR Marker Therapeutics	-0.80%	-15.07%	+0.81%	-12.68%	+43.10%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CDIO Cardio Diagnostics	1.00	Sell	N/A	N/A
ENLV Enlivex Therapeutics	2.50	Moderate Buy	$247.50	21,236.21% Upside
LGVN Longeveron	2.00	Hold	$80.00	1,115.81% Upside
MRKR Marker Therapeutics	2.25	Hold	$10.00	706.45% Upside

Current Analyst Ratings Breakdown

Latest CDIO, ENLV, MRKR, and LGVN Analyst Ratings

Date	Company	Brokerage	Action	Rating
8/25/2026	LGVN Longeveron	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/21/2026	MRKR Marker Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/21/2026	MRKR Marker Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/11/2026	LGVN Longeveron	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/6/2026	MRKR Marker Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/28/2026	LGVN Longeveron	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/21/2026	ENLV Enlivex Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
7/9/2026	LGVN Longeveron	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/26/2026	ENLV Enlivex Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
6/24/2026	MRKR Marker Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/23/2026	LGVN Longeveron	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CDIO Cardio Diagnostics	$10K	541.68	N/A	N/A	$2.51 per share	0.73
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	$122.21 per share	N/A
LGVN Longeveron	$1.20M	17.49	N/A	N/A	$3.26 per share	2.02
MRKR Marker Therapeutics	$3.55M	5.82	N/A	N/A	$0.73 per share	1.70

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CDIO Cardio Diagnostics	-$6.50M	-$2.92	N/A	N/A	N/A	-43,133.33%	-82.28%	-76.03%	11/6/2026 (Estimated)
ENLV Enlivex Therapeutics	$1.24B	-$8.25	N/A	N/A	N/A	N/A	248.08%	206.39%	9/4/2026 (Estimated)
LGVN Longeveron	-$22.70M	-$0.99	N/A	N/A	N/A	-1,977.59%	-223.19%	-150.20%	11/3/2026 (Estimated)
MRKR Marker Therapeutics	-$12.16M	-$0.41	N/A	N/A	N/A	-343.03%	-56.96%	-47.82%	11/12/2026 (Estimated)

Latest CDIO, ENLV, MRKR, and LGVN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/4/2026	Q1 2026	ENLV Enlivex Therapeutics	-$0.31	-$0.31	N/A	N/A	N/A	N/A
8/14/2026	Q2 2026	MRKR Marker Therapeutics	-$0.25	-$0.09	+$0.16	-$0.09	$0.68 million	N/A
8/12/2026	Q2 2026	LGVN Longeveron	-$1.75	-$1.90	-$0.15	-$0.19	$0.33 million	$0.29 million
8/7/2026	Q2 2026	CDIO Cardio Diagnostics	N/A	-$0.51	N/A	-$0.51	N/A	$0.01 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CDIO Cardio Diagnostics	N/A	N/A	N/A	N/A	N/A
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	N/A
LGVN Longeveron	N/A	N/A	N/A	N/A	N/A
MRKR Marker Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CDIO Cardio Diagnostics	N/A	17.16	17.16
ENLV Enlivex Therapeutics	N/A	193.24	193.24
LGVN Longeveron	N/A	2.63	2.63
MRKR Marker Therapeutics	N/A	6.03	6.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CDIO Cardio Diagnostics	8.06%
ENLV Enlivex Therapeutics	1.02%
LGVN Longeveron	10.01%
MRKR Marker Therapeutics	22.39%

Insider Ownership

Company	Insider Ownership
CDIO Cardio Diagnostics	8.99%
ENLV Enlivex Therapeutics	12.28%
LGVN Longeveron	7.42%
MRKR Marker Therapeutics	5.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CDIO Cardio Diagnostics	1	2.96 million	2.69 million	Not Optionable
ENLV Enlivex Therapeutics	70	17.49 million	15.34 million	Optionable
LGVN Longeveron	20	3.19 million	2.95 million	Not Optionable
MRKR Marker Therapeutics	60	16.67 million	15.72 million	Not Optionable

CDIO, ENLV, MRKR, and LGVN Headlines

Recent News About These Companies

Q3 EPS Forecast for Marker Therapeutics Boosted by Analyst

August 24, 2026 | americanbankingnews.com

Analysts Offer Insights on Healthcare Companies: Marker Therapeutics (MRKR) and CSPC Pharmaceutical Group (OtherCHJTF)

August 22, 2026 | theglobeandmail.com

Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker

June 26, 2026 | zacks.com

5 Small Drug Stocks to Invest in Amid a Biotech Comeback

June 25, 2026 | zacks.com

MARKER THERAPEUTICS (MRKR) Upgraded to Buy: What Does It Mean for the Stock?

May 20, 2026 | zacks.com

Marker Therapeutics Sets Date for 2026 Annual Meeting

May 19, 2026 | theglobeandmail.com

Marker Therapeutics (MRKR) price target decreased by 12.83% to 8.02

April 9, 2026 | msn.com

MARKER THERAPEUTICS, INC. (MRKR) Reports Q4 Loss, Tops Revenue Estimates

March 18, 2026 | zacks.com

Marker Therapeutics Reports Encouraging Phase 1 APOLLO Data and Corporate Developments in Immuno-Oncology

March 18, 2026 | quiverquant.comQ

Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results

March 18, 2026 | globenewswire.com

Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

February 18, 2026 | globenewswire.com

Good Morning America Features Baylor College of Medicine Pancreatic Cancer Study Utilizing Marker Therapeutics’ MAR-T Cell Technology

January 26, 2026 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Marker Therapeutics (MRKR), Pasithea Therapeutics Corp (KTTA) and TransMedics Group (TMDX)

January 22, 2026 | theglobeandmail.com

MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know

January 21, 2026 | zacks.com

Marker Therapeutics, Inc. Common Stock (MRKR)

January 9, 2026 | nasdaq.com

MARKER THERAPEUTICS, INC. (MRKR) Now Trades Above Golden Cross: Time to Buy?

January 7, 2026 | zacks.com

5 Small Drug Stocks to Buy as Industry Recovery Picks Up

January 7, 2026 | zacks.com

Marker Therapeutics announces publication on MAR-T cells in pancreatic cancer

January 5, 2026 | msn.com

Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer

January 5, 2026 | globenewswire.com

Here's Why Marker Therapeutics (NASDAQ:MRKR) Must Use Its Cash Wisely

December 18, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDIO, ENLV, MRKR, and LGVN Company Descriptions

Cardio Diagnostics NASDAQ:CDIO

$1.83 -0.01 (-0.54%)

As of 09/3/2026 04:00 PM Eastern

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.

Enlivex Therapeutics NASDAQ:ENLV

$1.16 -0.09 (-7.20%)

As of 09/3/2026 04:00 PM Eastern

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

Longeveron NASDAQ:LGVN

$6.58 -0.20 (-2.95%)

As of 09/3/2026 04:00 PM Eastern

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.

Marker Therapeutics NASDAQ:MRKR

$1.24 -0.01 (-0.80%)

As of 09/3/2026 04:00 PM Eastern

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CDIO, ENLV, MRKR, and LGVN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CDIO, ENLV, MRKR, and LGVN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CDIO, ENLV, MRKR, and LGVN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDIO, ENLV, MRKR, and LGVN Company Descriptions

Cardio Diagnostics NASDAQ:CDIO

Enlivex Therapeutics NASDAQ:ENLV

Longeveron NASDAQ:LGVN

Marker Therapeutics NASDAQ:MRKR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CDIO, ENLV, MRKR, and LGVN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CDIO, ENLV, MRKR, and LGVN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CDIO, ENLV, MRKR, and LGVN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDIO, ENLV, MRKR, and LGVN Company Descriptions

Cardio Diagnostics NASDAQ:CDIO

Enlivex Therapeutics NASDAQ:ENLV

Longeveron NASDAQ:LGVN

Marker Therapeutics NASDAQ:MRKR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools